Ⓐ
PeptiBrief
First in human trial· 2021

First-in-Human Study of MANP: A Novel ANP (Atrial Natriuretic Peptide) Analog in Human Hypertension

Chen HH|Wan SH|Iyer SR|Harty GJ|Boerrigter G|Burnett JC Jr

Hypertension

DOI
10.1161/hypertensionaha.121.18025
PubMed
34657445
Evidence level
moderate
Verification
verified

Summary

A first-in-human study evaluated MANP, an engineered atrial natriuretic peptide analogue, in adults with hypertension.

Limitations

Small early-phase study|Short follow-up|Specific engineered analogue|Does not generalise to all ANP analogues

Linked peptides

Important PeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.